CLRBEarnings•globenewswire•
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Sentiment:Negative (30)
Summary
Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire